drugset / Trial / NCT04381130
A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a multi center, open-label, dose escalation, Phase I/IIa study of EF-009 in up to 30 patients with borderline resectable and unresectable pancreatic cancer.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EF-009 | Unknown | — | Other |